Cargando…

Mesoporous Polydopamine Loaded Pirfenidone Target to Fibroblast Activation Protein for Pulmonary Fibrosis Therapy

Recently, fibroblast activation protein (FAP), an overexpressed transmembrane protein of activated fibroblast in pulmonary fibrosis, has been considered as the new target for diagnosing and treating pulmonary fibrosis. In this work, mesoporous polydopamine (MPDA), which is facile prepared and easily...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Qi, Liu, Shaoyu, Cui, Jiangyu, Zhao, Ruiyue, Han, Qian, Hou, Peng, Li, Youcai, Lv, Jie, Zhang, Xiaoyao, Luo, Qun, Wang, Xinlu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363109/
https://www.ncbi.nlm.nih.gov/pubmed/35957641
http://dx.doi.org/10.3389/fbioe.2022.920766
_version_ 1784764855969906688
author Fang, Qi
Liu, Shaoyu
Cui, Jiangyu
Zhao, Ruiyue
Han, Qian
Hou, Peng
Li, Youcai
Lv, Jie
Zhang, Xiaoyao
Luo, Qun
Wang, Xinlu
author_facet Fang, Qi
Liu, Shaoyu
Cui, Jiangyu
Zhao, Ruiyue
Han, Qian
Hou, Peng
Li, Youcai
Lv, Jie
Zhang, Xiaoyao
Luo, Qun
Wang, Xinlu
author_sort Fang, Qi
collection PubMed
description Recently, fibroblast activation protein (FAP), an overexpressed transmembrane protein of activated fibroblast in pulmonary fibrosis, has been considered as the new target for diagnosing and treating pulmonary fibrosis. In this work, mesoporous polydopamine (MPDA), which is facile prepared and easily modified, is developed as a carrier to load antifibrosis drug pirfenidone (PFD) and linking FAP inhibitor (FAPI) to realize lesion-targeted drug delivery for pulmonary fibrosis therapy. We have found that PFD@MPDA-FAPI is well biocompatible and with good properties of antifibrosis, when ICG labels MPDA-FAPI, the accumulation of the nanodrug at the fibrosis lung in vivo can be observed by NIR imaging, and the antifibrosis properties of PFD@MPDA-FAPI in vivo were also better than those of pure PFD and PFD@MPDA; therefore, the easily produced and biocompatible nanodrug PFD@MPDA-FAPI developed in this study is promising for further clinical translations in pulmonary fibrosis antifibrosis therapy.
format Online
Article
Text
id pubmed-9363109
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93631092022-08-10 Mesoporous Polydopamine Loaded Pirfenidone Target to Fibroblast Activation Protein for Pulmonary Fibrosis Therapy Fang, Qi Liu, Shaoyu Cui, Jiangyu Zhao, Ruiyue Han, Qian Hou, Peng Li, Youcai Lv, Jie Zhang, Xiaoyao Luo, Qun Wang, Xinlu Front Bioeng Biotechnol Bioengineering and Biotechnology Recently, fibroblast activation protein (FAP), an overexpressed transmembrane protein of activated fibroblast in pulmonary fibrosis, has been considered as the new target for diagnosing and treating pulmonary fibrosis. In this work, mesoporous polydopamine (MPDA), which is facile prepared and easily modified, is developed as a carrier to load antifibrosis drug pirfenidone (PFD) and linking FAP inhibitor (FAPI) to realize lesion-targeted drug delivery for pulmonary fibrosis therapy. We have found that PFD@MPDA-FAPI is well biocompatible and with good properties of antifibrosis, when ICG labels MPDA-FAPI, the accumulation of the nanodrug at the fibrosis lung in vivo can be observed by NIR imaging, and the antifibrosis properties of PFD@MPDA-FAPI in vivo were also better than those of pure PFD and PFD@MPDA; therefore, the easily produced and biocompatible nanodrug PFD@MPDA-FAPI developed in this study is promising for further clinical translations in pulmonary fibrosis antifibrosis therapy. Frontiers Media S.A. 2022-07-22 /pmc/articles/PMC9363109/ /pubmed/35957641 http://dx.doi.org/10.3389/fbioe.2022.920766 Text en Copyright © 2022 Fang, Liu, Cui, Zhao, Han, Hou, Li, Lv, Zhang, Luo and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Fang, Qi
Liu, Shaoyu
Cui, Jiangyu
Zhao, Ruiyue
Han, Qian
Hou, Peng
Li, Youcai
Lv, Jie
Zhang, Xiaoyao
Luo, Qun
Wang, Xinlu
Mesoporous Polydopamine Loaded Pirfenidone Target to Fibroblast Activation Protein for Pulmonary Fibrosis Therapy
title Mesoporous Polydopamine Loaded Pirfenidone Target to Fibroblast Activation Protein for Pulmonary Fibrosis Therapy
title_full Mesoporous Polydopamine Loaded Pirfenidone Target to Fibroblast Activation Protein for Pulmonary Fibrosis Therapy
title_fullStr Mesoporous Polydopamine Loaded Pirfenidone Target to Fibroblast Activation Protein for Pulmonary Fibrosis Therapy
title_full_unstemmed Mesoporous Polydopamine Loaded Pirfenidone Target to Fibroblast Activation Protein for Pulmonary Fibrosis Therapy
title_short Mesoporous Polydopamine Loaded Pirfenidone Target to Fibroblast Activation Protein for Pulmonary Fibrosis Therapy
title_sort mesoporous polydopamine loaded pirfenidone target to fibroblast activation protein for pulmonary fibrosis therapy
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363109/
https://www.ncbi.nlm.nih.gov/pubmed/35957641
http://dx.doi.org/10.3389/fbioe.2022.920766
work_keys_str_mv AT fangqi mesoporouspolydopamineloadedpirfenidonetargettofibroblastactivationproteinforpulmonaryfibrosistherapy
AT liushaoyu mesoporouspolydopamineloadedpirfenidonetargettofibroblastactivationproteinforpulmonaryfibrosistherapy
AT cuijiangyu mesoporouspolydopamineloadedpirfenidonetargettofibroblastactivationproteinforpulmonaryfibrosistherapy
AT zhaoruiyue mesoporouspolydopamineloadedpirfenidonetargettofibroblastactivationproteinforpulmonaryfibrosistherapy
AT hanqian mesoporouspolydopamineloadedpirfenidonetargettofibroblastactivationproteinforpulmonaryfibrosistherapy
AT houpeng mesoporouspolydopamineloadedpirfenidonetargettofibroblastactivationproteinforpulmonaryfibrosistherapy
AT liyoucai mesoporouspolydopamineloadedpirfenidonetargettofibroblastactivationproteinforpulmonaryfibrosistherapy
AT lvjie mesoporouspolydopamineloadedpirfenidonetargettofibroblastactivationproteinforpulmonaryfibrosistherapy
AT zhangxiaoyao mesoporouspolydopamineloadedpirfenidonetargettofibroblastactivationproteinforpulmonaryfibrosistherapy
AT luoqun mesoporouspolydopamineloadedpirfenidonetargettofibroblastactivationproteinforpulmonaryfibrosistherapy
AT wangxinlu mesoporouspolydopamineloadedpirfenidonetargettofibroblastactivationproteinforpulmonaryfibrosistherapy